x

Posted 26 January, 2023

Kronos Bio, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:KRON in a 8-K filed on 26 January, 2023.


  On January 21, 2023, Marianne De Backer, Ph.D., notified us of her decision to resign from our board of directors as a result of her recent appointment as Chief Executive Officer of Vir Biotechnology, Inc., and in consideration of her additional time commitments associated with such position, as well as the "overboarding" policies of shareholder advisory firms.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Kronos Bio, Inc.
Health Care/Life Sciences • Biotechnology
Kronos Bio, Inc. is a clinical-stage biopharmaceutical, which engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic transcription factors, small cell, prostate cancer, and MYC-driven cancers. The company was founded by Angela Koehler and Joshua Kazam in 2017 and is headquartered in Cambridge, MA.
Market Cap
$57.3M
View Company Details
Kronos Bio, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(b)


On January 21, 2023, Marianne De Backer, Ph.D., notified us of her decision to resign from our board of directors as a result of her recent appointment as Chief Executive Officer of Vir Biotechnology, Inc., and in consideration of her additional time commitments associated with such position, as well as the "overboarding" policies of shareholder advisory firms. The effective date of the resignation has not yet been established, but Dr. De Backer informed us it would likely be late in the first quarter or in the second quarter of 2023. We will file an amendment to this current report on Form 8-K to report the effective date of Dr. De Backer's resignation within four business days of the effective date being determined.